

Freedom of Information Act 2000 - Request Reference Fol/22/306
Dermatology Treatments

Information Requested:

How many patients were treated in June 2022 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibinqo)
- Baricitinib (Olumiant)
- Bimekizumab (Bimzelx)
- Brodalumab (Kyntheum)
- Dupilumab (Dupixent)
- Ixekizumab (Taltz)
- Risankizumab (Skyrizi)
- Guselkumab (Tremfya)
- Secukinumab (Cosentyx)
- Tildrakizumab (Ilumetri)
- Tralokinumab (Adtralza)
- Upadacitinib (Rinvoq)
- Ustekinumab (Stelara)

Response Details

Abrocitinib (Cibinqo)	0
Baricitinib (Olumiant)	1
Bimekizumab (Bimzelx)	1
Brodalumab (Kyntheum)	2
Dupilumab (Dupixent)	42
Ixekizumab (Taltz)	6
Risankizumab (Skyrizi)	9
Guselkumab (Tremfya)	11
Secukinumab (Cosentyx)	25
Tildrakizumab (Ilumetri)	0
Tralokinumab (Adtralza)	0
Upadacitinib (Rinvoq)	0
Ustekinumab (Stelara)	13